SELLAS Life Sciences Group, Inc.

SLS Healthcare Biotechnology

SELLAS Life Sciences Group, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.0 million. In the quarter to June 2026, EPS grew 28.6% and free cash flow fell 3.52%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

9.98 1.36 −11.99%
Market cap
$2.3B
P/E
0.0×
Fwd P/E
−10.0×
Dividend yield
—
F-score
2/9
Altman Z
−16.75
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
18.83 17.22 10.72 8.28
Net Debt/EBITDA
13.03 11.59 8.71 6.27
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.04) (0.05) (0.05) (0.07)
Book value per Share
0.73 0.62 0.65 0.42
Free Cash Flow
(7.59) (8.85) (4.92) (7.07)
Other line items

Show all line items

Columns are period end dates